1-3 of 3
Michelle Brooker-McEldowney
Close
Sort by
Journal Articles

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Clinical Trials & Observations
Mitch A. Phelps, Thomas S. Lin, Amy J. Johnson, Eunju Hurh, Darlene M. Rozewski, Katherine L. Farley, Di Wu, Kristie A. Blum, Beth Fischer, Sarah M. Mitchell, Mollie E. Moran, Michelle Brooker-McEldowney, Nyla A. Heerema, David Jarjoura, Larry J. Schaaf, John C. Byrd, Michael R. Grever, James T. Dalton
Journal: Blood
Blood (2009) 113 (12): 2637–2645.
https://doi.org/10.1182/blood-2008-07-168583
Published: 2009
Journal Articles

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Thomas S. Lin, James T. Dalton, Di Wu, Mitch A. Phelps, Beth Fischer, Mollie Moran, Kristie A. Blum, Brad Rovin, Michelle Brooker-McEldowney, Sarah Broering, Larry J. Schaaf, Amy J. Johnson, David M. Lucas, Nyla A. Heerema, Gerard Lozanski, Donn C. Young, Jose-Ramon Suarez, A. Dimitrios Colevas, Michael R. Grever
Journal: Blood
Blood (2006) 109 (2): 399–404.
https://doi.org/10.1182/blood-2006-05-020735
Published: 2006
Journal Articles

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.

Mollie E. Moran, MSN, Beth Fischer, MSN, Sara Broering, BS, Kristie A. Blum, MD, Thomas S. Lin, MD, PhD, John C. Byrd, MD, Michael R. Grever, MD, Michelle Brooker-McEldowney, MSN
Journal: Blood
Blood (2005) 106 (11): 2124.
https://doi.org/10.1182/blood.V106.11.2124.2124
Published: 2005